Advanced

Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting β2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.

Bjermer, Leif LU ; Rosenborg, Johan ; Bengtsson, Thomas and Lötvall, Jan (2013) In Therapeutic Advances in Respiratory Disease 7(5). p.264-271
Abstract
Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This single-dose crossover study was conducted to investigate and compare with formoterol the bronchodilatory and systemic effects, tolerability and safety of AZD3199, a novel ultra-long-acting β2-agonist (uLABA).
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Therapeutic Advances in Respiratory Disease
volume
7
issue
5
pages
264 - 271
publisher
SAG
external identifiers
  • pmid:23907810
  • wos:000336024400002
  • scopus:84884570872
  • pmid:23907810
ISSN
1753-4666
DOI
10.1177/1753465813497527
language
English
LU publication?
yes
id
53c3e011-6b31-4fb7-a9de-9d42685836c1 (old id 4006265)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23907810?dopt=Abstract
date added to LUP
2016-04-01 10:16:56
date last changed
2020-01-05 05:34:31
@article{53c3e011-6b31-4fb7-a9de-9d42685836c1,
  abstract     = {Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This single-dose crossover study was conducted to investigate and compare with formoterol the bronchodilatory and systemic effects, tolerability and safety of AZD3199, a novel ultra-long-acting β2-agonist (uLABA).},
  author       = {Bjermer, Leif and Rosenborg, Johan and Bengtsson, Thomas and Lötvall, Jan},
  issn         = {1753-4666},
  language     = {eng},
  number       = {5},
  pages        = {264--271},
  publisher    = {SAG},
  series       = {Therapeutic Advances in Respiratory Disease},
  title        = {Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting β2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.},
  url          = {http://dx.doi.org/10.1177/1753465813497527},
  doi          = {10.1177/1753465813497527},
  volume       = {7},
  year         = {2013},
}